PPC
NBIX icon

Park Place Capital’s Neurocrine Biosciences NBIX Stock Holding History

Park Place Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7K Hold
16
– – ﹤0.01% 983
2026
Q1 		$2.11K Hold
16
– – ﹤0.01% 750
2025
Q4 		$2.27K Hold
16
– – ﹤0.01% 705
2025
Q3 		$2.25K Hold
16
– – ﹤0.01% 695
2025
Q2 		$2.05K Hold
16
– – ﹤0.01% 728
2025
Q1 		$1.77K Hold
16
– – ﹤0.01% 746
2024
Q4 		$2.18K Hold
16
– – ﹤0.01% 723
2024
Q3 		$1.84K Hold
16
– – ﹤0.01% 775
2024
Q2 		$2.2K Hold
16
– – ﹤0.01% 763
2024
Q1 		$2.21K Hold
16
– – ﹤0.01% 813
2023
Q4 		$2.11K Hold
16
– – ﹤0.01% 794
2023
Q3 		$1.8K Hold
16
– – ﹤0.01% 934
2023
Q2 		$1.51K Sell
16
-705
-98% -$68.9K ﹤0.01% 972
2023
Q1 		$73K Buy
721
+9
+1% +$937 0.02% 418
2022
Q4 		$85K Buy
+712
New +$83.4K 0.02% 384

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Park Place Capital's NBIX Position: Q2 2026 in Review

Park Place Capital held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 16 shares worth $2.7K. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Park Place Capital first reported a position in NBIX in Q4 2022 and has held it in 15 quarters since. The position peaked at $85K in Q4 2022. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Park Place Capital held 16 shares of Neurocrine Biosciences worth $2.7K as of Q2 2026.
  • Park Place Capital left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #983 holding.
  • Park Place Capital first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 15 quarters since.
  • Park Place Capital's Neurocrine Biosciences position peaked at $85K in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.